Cost Per Visit Trends Higher for Less Established Regions
IMS Health
Many factors affect a sponsor's decision to pick a region in which to conduct a clinical trial. Clinical grant expenditures represent a significant portion of later phase clinical trial budgets. Therefore, the relative cost per visit can play a large role in which region to select.
Figure 1. Cost per visit rate trends, 2008-2010 and 2011-2013.
IMS Health's current analysis demonstrates that the cost per patient visit in the newer, emerging geographies, is growing more rapidly than in more established regions. The established regions (Western Europe, US/Canada, and Australia/New Zealand) have been averaging 8% annual increases from 2011-2013, while grant costs in developing regions (East Asia, Latin America, and Eastern Europe) are growing at two to three times those rates with an average of 23%. Even if these emerging regions are starting off on a lower base as compared to well established regions, the rapid rise in cost in these regions warrant careful consideration in the coming years.
—IMS Health (for more information contact clinicaltrials@us.imshealth.com)
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
